Literature DB >> 17101684

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.

Manjunath P Pai1, Robin S Turpin, Kevin W Garey.   

Abstract

The present study tested in vitro susceptibility of Candida bloodstream isolates to fluconazole to determine if the ratio of the fluconazole area under the concentration-time curve (AUC) or weight-normalized daily dose (dose(wn)) to MIC correlated with mortality. Fluconazole susceptibility and outcome data were determined for 77 patients with a positive Candida blood culture between 2002 and 2005. The most commonly isolated Candida species were C. albicans (64%), C. glabrata (14%), C. parapsilosis (8%), C. tropicalis (6%), and C. lusitaniae (4%). Only two isolates were classified as fluconazole resistant by the CLSI M27-A2 method. Fluconazole MICs were highest against C. glabrata relative to other Candida species. Overall the crude mortality assessed at hospital discharge was 19.4% (n = 15). Mortality rates by species were as follows: C. albicans, 16.3%; C. glabrata, 36.4%; C. parapsilosis, 0%; C. tropicalis, 0%; C. lusitaniae, 33.3%. A mortality rate of 50% was noted among patients infected with nonsusceptible isolates (MIC > or = 16 microg/ml) compared to 18% for patients infected with susceptible (MIC < or = 8 microg/ml) isolates (P = 0.17). The fluconazole dose(wn)/MIC (24-h) values were significantly higher for the 62 survivors (13.3 +/- 10.5 [mean +/- standard deviation]) compared to the 15 nonsurvivors (7.0 +/- 8.0) (P = 0.03). The fluconazole AUC/MIC (24 h) values also trended higher for survivors (775 +/- 739) compared to nonsurvivors (589 +/- 715) (P = 0.09). These data support the dose-dependent properties of fluconazole. Underdosing fluconazole against less-susceptible Candida isolates has the potential to increase the risk of mortality associated with candidemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101684      PMCID: PMC1797664          DOI: 10.1128/AAC.00474-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Breakpoints: current practice and future perspectives.

Authors:  Johan W Mouton
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

2.  Antifungal susceptibility testing in teaching hospitals.

Authors:  Manjunath P Pai; Susan L Pendland
Journal:  Ann Pharmacother       Date:  2003-02       Impact factor: 3.154

3.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

4.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

5.  Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

Authors:  S C Lee; C P Fung; J S Huang; C J Tsai; K S Chen; H Y Chen; N Lee; L C See; W B Shieh
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; C B Moore; F Barchiesi; J Bille; E Chryssanthou; D W Denning; J P Donnelly; F Dromer; B Dupont; J H Rex; M D Richardson; B Sancak; P E Verweij; J L Rodríguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

7.  In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.

Authors:  Anastasia Antoniadou; Harrys A Torres; Russell E Lewis; John Thornby; Gerald P Bodey; Jeffrey P Tarrand; Xiang-Yang Han; Kenneth V I Rolston; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

9.  Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Authors:  D Andes; K Marchillo; R Conklin; Gopal Krishna; Farkad Ezzet; Anthony Cacciapuoti; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  49 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.

Authors:  J M Boonstra; A G Märtson; I Sandaradura; J G W Kosterink; T S van der Werf; D J E Marriott; J G Zijlstra; D J Touw; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; J Peter Donnelly; Cornelia Lass-Flörl; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-06       Impact factor: 5.191

Review 4.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Susceptible, intermediate, and resistant - the intensity of antibiotic action.

Authors:  Arne Rodloff; Torsten Bauer; Santiago Ewig; Peter Kujath; Eckhard Müller
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594

6.  Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Authors:  Isabel Cuesta; Concha Bielza; Manuel Cuenca-Estrella; Pedro Larrañaga; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

7.  Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Authors:  Pier Giorgio Cojutti; Manuela Lugano; Elda Righi; Giorgio Della Rocca; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-07-21       Impact factor: 2.953

8.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

9.  Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.

Authors:  Katsuyuki Maki; Shuji Kaneko
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-03-29       Impact factor: 2.441

10.  Determinants of mortality in non-neutropenic ICU patients with candidaemia.

Authors:  Deborah J E Marriott; E Geoffrey Playford; Sharon Chen; Monica Slavin; Quoc Nguyen; David Ellis; Tania C Sorrell
Journal:  Crit Care       Date:  2009-07-13       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.